| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H10FNO3 |
| Molecular Weight | 271.2432 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=CC2=C(OC(=N2)C3=CC=C(O)C(F)=C3)C(C=C)=C1
InChI
InChIKey=MQIMZDXIAHJKQP-UHFFFAOYSA-N
InChI=1S/C15H10FNO3/c1-2-8-5-10(18)7-12-14(8)20-15(17-12)9-3-4-13(19)11(16)6-9/h2-7,18-19H,1H2
Prinaberel is a selective agonist of estrogen receptor beta. Although initially developed for the treatment of endometriosis, the drug was also shown to be effective in vitro in other inflammatory diseases. Phase II clinical studied revealed its effectiveness in case of Crohn's disease and endometriosis, but the drug failed to demonstrate antiinflammatory efficacy in RA patients.
Originator
Approval Year
Doses
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
Drug as victim
PubMed
Patents
Sample Use Guides
In phase II patients received 5, 25, or 75 mg of prinaberel for 12 weeks.
Route of Administration:
Oral
ACTIVE MOIETY
